Three double-stapled peptides held off respiratory syncytial virus in cells and in mice. The same three peptides kept working against viral strains that had evolved resistance to the small-molecule fusion inhibitor class. The peptides are called 3/4i, 3/4m, and 4/4g, all derived from a minimal stretch of the RSV F protein's heptad repeat. The paper went online May 27 in the Journal of Medicinal Chemistry ↗.
RSV is a major respiratory pathogen, with the heaviest disease burden at the two ends of the age spectrum. Small-molecule fusion inhibitors targeting RSV's F protein have been in development for two decades. Several have reached the clinic. The problem each one inherits is the problem any small-molecule antiviral inherits. Viral populations under selection rapidly fix mutations that knock down the binding pocket, and the molecule no longer works.
The mechanism a stapled peptide uses is different. RSV fuses with the host cell by collapsing two helical regions of its F protein, HR1 and HR2, into a tight six-helix bundle. A peptide derived from HR2 can intercalate into the HR1 trimer and freeze the F protein in a pre-fusion state, blocking entry. The architectural problem with using a bare HR2 peptide is that linear peptides without secondary-structure constraints lose their helical shape in solution and get cleaved by proteases. A staple, in the chemistry sense, is a covalent bridge installed between two amino-acid side chains separated by a few residues. It locks the backbone into the helical conformation the peptide needs, and incidentally protects against proteolysis.
The team screened a library of double-stapled candidates, varying staple positions and lengths inside the same RSV F-derived sequence, and identified three that emerged as the most potent: 3/4i, 3/4m, and 4/4g. The structure-activity analysis is the practical part of the paper. A small set of staple placements is enough to land on high antiviral potency. The team did not need exotic chemistry to get there.
The escape-mutant result is the head-turner. The authors tested the three stapled peptides against RSV variants that had been selected for resistance against existing small-molecule fusion inhibitors, the kind of virus that has slipped the pharmacology of that class. The stapled peptides kept blocking those variants. The explanation, supported by X-ray crystallography in the paper, is that the stapled peptides contact a longer stretch of the HR1 coiled-coil surface than a single small molecule ever does. Specifically, the N-terminal staple drives strong hydrophobic interactions with the HR1 coil. Mutations that swap a few residues to evade a small-molecule pocket cannot evade contacts distributed across many residues at once.
The in-vivo work, in RSV-infected Balb/c mice, was about getting the peptide to the right tissue. The team tested intranasal delivery, sampled pharmacokinetics, and imaged the peptide's distribution. Intranasal worked. The peptide reached the lung at levels consistent with antiviral activity. That is the route that matters for a respiratory antiviral. Infections happen in the airway epithelium, and a drug that arrives there from a nasal spray clears a different regulatory and patient-acceptance bar than one that has to be injected.
What is not yet in the paper is the next step. Whether the peptides retain potency across the full geographic spread of circulating RSV strains, whether immunogenicity opens up after repeat dosing, and whether the manufacturing economics of a double-stapled peptide line up with the cost target for a respiratory antiviral are all open questions. None of them get answered by a Journal of Medicinal Chemistry paper. The chemistry is shown. The development case begins after it.
For the broader field, the result is a worked example of a long-standing argument. When a viral protein offers a long, contiguous interface, as RSV F's HR1 coiled-coil does, a stapled peptide can engage the surface across a stretch wide enough that escape mutations have to break multiple contacts at once. That is the situation where peptides beat small molecules on resistance. RSV F is one of the cleanest test cases for it that the field has.